Early Graft Function in Deceased Donor Renal Recipients: Role of N-Acetylcysteine

Document Type : Research article

Authors

1 Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.

2 Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Chronic Kidney Disease Research Center, Shahid Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Department of Clinical Pharmacy, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Reduced graft function (RGF) in donor renal transplant recipients is caused by oxidative damage due to extensive ischemia-reperfusion (I/R) injury during transplantation. Neutrophil gelatinase-associated lipocalin (NGAL) is a promising biomarker to detect tubular injury early after renal transplantation. N-acetylcysteine (NAC) is a potent antioxidant that can reduce I/R injury by improving oxidative damage. The aim of the present study is to assess the efficacy of NAC in improving graft function and reducing renal tubular injury in deceased donor renal transplant recipients. A double-blind, randomized clinical trial was conducted on 50 deceased donor renal transplant recipients. Patients were randomized into two groups, receiving either 600 mg NAC twice daily, or placebo (days 0 to 5). Results were assessed based on the rate of RGF, levels of plasma NGAL (p-NGAL) and the estimated glomerular filtration rate (eGFR). The rate of RGF was significantly lower in patients receiving NAC vs. placebo (21.4% vs. 50%). The measurement of p-NGAL levels showed that patients in the NAC group had significantly greater reduction of p-NGAL by both days 1 and 5 post-transplantation than those in the placebo group. A near steady-state eGFR level was reached by week 1 in the NAC group, however, the improvement of eGFR was significantly slower in the placebo group and a near steady-state was only achieved by week 4. NAC has promising potential in reducing tubular injury and improving graft function, evidenced by significant reduction in the rate of RGF and levels of p-NGAL.

Graphical Abstract

Early Graft Function in Deceased Donor Renal Recipients: Role of N-Acetylcysteine

Keywords

Main Subjects



(1) Siedlecki A, Irish W and Brennan DC. Delayed graftfunction in the kidney transplant. Am. J. Transplant.(2011) 11: 2279-96.
(2) Nel D, Vogel J, Muller E, Barday Z and Kahn D.Slow early graft function: a neglected entity afterrenal transplantation. Nephron Clin. Pract. (2012)120: c200-4.
(3) Khalkhali HR, Ghafari A, Hajizadeh E andKazemnejad A. Risk factors of long-term graft lossin renal transplant recipients with chronic allograftdysfunction. Exp. Clin. Transplant. (2010) 8:277-82.
(4) Zelenetz AD, Abramson JS, Advani RH, AndreadisCB, Byrd JC, Czuczman MS, Fayad L, Forero A,Glenn MJ, Gockerman JP, Gordon LI, Harris NL,Hoppe RT, Horwitz SM, Kaminski MS, Kim YH,LaCasce AS, Mughal TI, Nademanee A, Porcu P,Press O, Prosnitz L, Reddy N, Smith MR, SokolL, Swinnen L, Vose JM, Wierda WG, Yahalom Jand Yunus F. Non-Hodgkin’s Lymphomas. J. Natl.Compr Canc. Netw. (2010) 8: 288-334.
(5) Johnston O, O’Kelly P, Spencer S, Donohoe J,Walshe JJ, Little DM, Hickey D and Conlon PJ.Reduced graft function (with or without dialysis) vsimmediate graft function--a comparison of long-term renal allograft survival. Nephrol Dial Transplant. (2006) 21: 2270-4.
(6) Nafar M, Sahraei Z, Salamzadeh J, Samavat S and Vaziri ND. Oxidative stress in kidney transplantation: causes, consequences, and potential treatment. Iran. J. Kidney. Dis. (2011) 5: 357-72.
(7) Peeters P and Vanholder R. Therapeutic interventions favorably influencing delayed and slow graft function in kidney transplantation: mission impossible? Transplantation (2008) 85: S31-7.
(8) Kelly AM, Dwamena B, Cronin P, Bernstein SJ andCarlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann. Intern. Med. (2008) 148: 284-94.
(9) Harrison EM, Sharpe E, Bellamy CO, McNally SJ, Devey L, Garden OJ, Ross JA and Wigmore SJ. Heat shock protein 90-binding agents protect renal cells from oxidative stress and reduce kidney ischemiareperfusion injury. Am. J. Physiol. Renal. Physiol. (2008) 295: F397-405.
(10) Sehirli AO, Sener G, Satiroglu H and AyanogluDulger G. Protective effect of N-acetylcysteine on renal ischemia/reperfusion injury in the rat. J. Nephrol. (2003) 16: 75-80.
(11) Nitescu N, Ricksten SE, Marcussen N, Haraldsson B, Nilsson U, Basu S and Guron G. N-acetylcysteine attenuates kidney injury in rats subjected to renal
ischaemia-reperfusion. Nephrol Dial Transplant. (2006) 21: 1240-7.
(12) Danilovic A, Lucon AM, Srougi M, Shimizu MH, Ianhez LE, Nahas WC and Seguro AC. Protective effect of N-acetylcysteine on early outcomes of deceased renal transplantation. Transplant Proc. (2011) 43: 1443-9.
(13) Orban JC, Quintard H, Cassuto E, Jambou P, SamatLong C and Ichai C. Effect of N-acetylcysteine pretreatment of deceased organ donors on renal allograft function: a randomized controlled trial. Transplantation (2015) 99: 746-53.
(14) Ruiz Fuentes MC, Moreno Ayuso JM, Ruiz Fuentes N, Vargas Palomares JF, Asensio Peinado C and Osuna Ortega A. Treatment with N-acetylcysteine in stable renal transplantation. Transplant Proc. (2008) 40: 2897-9.
(15) Murray PT, Devarajan P, Levey AS, Eckardt KU, Bonventre JV, Lombardi R, Herget-Rosenthal S and Levin A. A framework and key research questions in AKI diagnosis and staging in different environments. Clin. J. Am. Soc. Nephrol. (2008) 3: 864-8.
(16) Peake PW, Pianta TJ, Succar L, Fernando M, Pugh DJ, McNamara K and Endre ZH. A comparison of the ability of levels of urinary biomarker proteins and exosomal mRNA to predict outcomes after renal transplantation. PLoS One (2014) 9: e98644. 67 Role of N-Acetylcysteine
(17) Hall IE, Doshi MD, Poggio ED and Parikh CR. A comparison of alternative serum biomarkers with creatinine for predicting allograft function after kidney transplantation. Transplantation (2011) 91: 48-56.
(18) Hollmen ME, Kyllonen LE, Inkinen KA, Lalla ML, Merenmies J and Salmela KT. Deceased donor neutrophil gelatinase-associated lipocalin and delayed graft function after kidney transplantation: a prospective study. Crit. Care (2011) 15: R121.
(19) Nishida M, Kawakatsu H, Okumura Y and Hamaoka K. Serum and urinary neutrophil gelatinaseassociated lipocalin levels in children with chronic renal diseases. Pediatr. Int. (2010) 52: 563-8.
(20) Buemi A, Musuamba F, Frederic S, Douhet A, De Meyer M, De Pauw L, Darius T, Kanaan N, Wallemacq P and Mourad M. Is plasma and urine neutrophil gelatinase-associated lipocalin (NGAL) determination in donors and recipients predictive of renal function after kidney transplantation? Clin. Biochem. (2014) 47: 68-72.
(21) Magnusson NE, Hornum M, Jorgensen KA, Hansen JM, Bistrup C, Feldt-Rasmussen B and Flyvbjerg A. Plasma neutrophil gelatinase associated lipocalin (NGAL) is associated withkidney function in uraemic patients before and after kidney transplantation. BMC Nephrol. (2012) 13: 8.
(22) Hall IE, Yarlagadda SG, Coca SG, Wang Z, Doshi M, Devarajan P, Han WK, Marcus RJ and Parikh CR. IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J. Am. Soc. Nephrol. (2010) 21: 189-97.
(23) Singh S, Kumar S, Dasgupta S, Kenwar D, Rathi M, Sharma A, Kohli H, Jha V, Gupta K and Minz M. A single-center experience of kidney transplantation from donation after circulatory death: Challenges and scope in India. Indian J. Nephrol. (2017) 27: 205-09.
(24) Boom H, Mallat MJ, de Fijter JW, Zwinderman AH and Paul LC. Delayed graft function influences renal function, but not survival. Kidney Int. (2000) 58: 859-66.
(25) Rodrigo E, Ruiz JC, Pinera C, Fernandez-FresnedoG, Escallada R, Palomar R, Cotorruelo JG, Zubimendi JA, Martin de Francisco AL and Arias M. Creatinine reduction ratio on post-transplant day two as criterion in defining delayed graft function. Am. J. Transplant. (2004) 4: 1163-9.
(26) Ojo AO, Wolfe RA, Held PJ, Port FK and Schmouder RL. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation (1997) 63: 968-74.
(27) Cugini D, Azzollini N, Gagliardini E, Cassis P, Bertini R, Colotta F, Noris M, Remuzzi G and Benigni A. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int. (2005) 67: 1753-61.
(28) Sahraei Z, Salamzadeh J and Nafar M. Effect of N-acetyl cysteine and vitamin C on kidney allograft function biomarkers interleukin-18 and neutrophil gelatinase-associated lipocalin. Iran. J. Kidney Dis. (2015) 9: 56-62.
(29) Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am. Soc. Nephrol. (2008) 3: 281-7.
(30) Shimizu MH, Danilovic A, Andrade L, VolpiniRA, Liborio AB, Sanches TR and Seguro AC.N-acetylcysteine protects against renal injury following bilateral ureteral obstruction. Nephrol. Dial. Transplant. (2008) 23: 3067-73.
(31) Siedlecki A, Irish W and Brennan DC. Delayed Graft Function in the Kidney Transplant. Am. J.
Transplant. (2011) 11: 2279-96.
(32) Salvadori M, Rosso G and Bertoni E. Update on ischemia-reperfusion injury in kidney transplantation: Pathogenesis and treatment. World J. Transplant. (2015) 5: 52-67.